TRIM25: Tripartite Motif Containing 25
E3 ubiquitin-protein ligase involved in innate immunity and cancer
Gene Information Card
| Symbol | TRIM25 |
|---|---|
| Full Name | Tripartite Motif Containing 25 |
| Gene Type | Protein coding |
| Chromosomal Location | 17q22 |
| NCBI Gene ID | 7706 ncbi.nlm.nih.gov/gene/7706 |
| Ensembl ID | ENSG00000121060 |
| UniProt ID | Q14258 |
| OMIM ID | 604357 |
| HGNC ID | 16271 |
| Aliases | EFP, ZNF147, RNF147, UIP28 |
Description
TRIM25 (tripartite motif containing 25) encodes a member of the tripartite motif (TRIM) family. The protein functions as an E3 ubiquitin-protein ligase, catalyzing the ubiquitination of target proteins. It is best known for its role in innate antiviral immunity by mediating the ubiquitination of the cytosolic RNA sensor RIG-I (DDX58), which is essential for RIG-I activation and downstream interferon signaling. TRIM25 also participates in estrogen receptor signaling and has been implicated in various cancers, including breast cancer, where it can act as an oncogene or tumor suppressor depending on context.
Disease Associations
| Disease category | Pathophysiological mechanism | Genomic evidence |
|---|---|---|
| Breast Cancer | TRIM25 overexpression enhances estrogen receptor alpha (ERα) transcriptional activity and promotes cell proliferation; also linked to tamoxifen resistance. | PMID: 15601869, PMID: 21502522 |
| Viral Infections (Influenza, Dengue) | TRIM25-mediated RIG-I ubiquitination is critical for interferon induction; viruses such as influenza A and dengue virus target TRIM25 to evade immune response. | PMID: 17981124, PMID: 25146922 |
| Colorectal Cancer | TRIM25 is upregulated and associated with poor prognosis; promotes Wnt/β-catenin signaling. | PMID: 28411371 |
| Ovarian Cancer | TRIM25 expression correlates with tumor grade and metastasis; may regulate p53 stability. | PMID: 25944712 |
Expression Profile
Tissue Expression
| Tissue | nTPM | level |
|---|---|---|
| Breast | 12.3 | Medium |
| Lung | 8.7 | Medium |
| Liver | 6.2 | Low |
| Kidney | 5.1 | Low |
| Testis | 15.8 | High |
| Lymph node | 9.4 | Medium |
Cell Line Expression
| Cell Line | nTPM | Notes |
|---|---|---|
| MCF7 (breast cancer) | 14.2 | ER-positive; high TRIM25 expression |
| A549 (lung cancer) | 10.1 | Moderate expression |
| HepG2 (liver cancer) | 7.3 | Low expression |
| HEK293 (embryonic kidney) | 11.5 | Common model for TRIM25 studies |
Data source:Human Protein Atlas(proteinatlas.org)
Mutations & Variants
Hotspot Mutations
| Variant | Type | Frequency | Functional Description |
|---|---|---|---|
| c.1015C>T (p.Arg339Trp) | Missense | <0.01% | Unknown; rare variant in population databases |
| c.1246G>A (p.Glu416Lys) | Missense | <0.01% | Reported in breast cancer; functional impact unclear |
| c.1630_1631insA (p.Thr544Asnfs*2) | Frameshift | <0.01% | Predicted loss of function; observed in colorectal cancer |
Mutation functional classification
Loss of Function (LOF)
Frameshift and nonsense mutations that truncate the RING or coiled-coil domains impair E3 ligase activity and RIG-I ubiquitination.
Gain of Function (GOF)
Missense mutations in the SPRY domain may enhance substrate binding or alter specificity, but evidence is limited.
Dominant Negative (DN)
Mutations in the RING domain that disrupt zinc coordination can produce dominant-negative effects by sequestering substrates or blocking wild-type TRIM25.
View complete mutation data:
Gene Ontology (GO)
| • GO:0004842 - ubiquitin-protein transferase activity | • GO:0005515 - protein binding |
| • GO:0008270 - zinc ion binding | • GO:0016567 - protein ubiquitination |
| • GO:0032481 - positive regulation of type I interferon production | • GO:0045087 - innate immune response |
| • GO:0061630 - ubiquitin protein ligase activity |
Pathways
• RIG-I/MDA5 mediated induction of interferon-alpha/beta (Reactome: R-HSA-936440)
• Antiviral mechanism by IFN-stimulated genes (Reactome: R-HSA-1169410)
• Estrogen-dependent gene expression (Reactome: R-HSA-8939211)
Protein Summary
TRIM25 is a 72 kDa protein containing an N-terminal RING finger domain, two B-box domains, a coiled-coil region, and a C-terminal SPRY domain. The RING domain confers E3 ubiquitin ligase activity, while the SPRY domain mediates substrate recognition. TRIM25 is primarily cytoplasmic and undergoes self-ubiquitination. Its best-characterized substrate is RIG-I, where TRIM25 attaches K63-linked polyubiquitin chains to the CARD domains, enabling RIG-I to activate MAVS and trigger interferon production. TRIM25 also ubiquitinates other targets including p53, ZAP, and ERα, linking it to both antiviral defense and cancer biology.
Related Services
Related Products
| Product name | Cat.No. | Species | Gene ID | |
|---|---|---|---|---|
| TRIM25 Knockout HEK293 Cell Line | EDJ-KQ604 | Human | 7706 | Details Get a Quote |
| TRIM25 Knockout A-549 Cell Line | EDC09755 | Human | 7706 | Details Get a Quote |
| TRIM25 Knockout HCT 116 Cell Line | EDJ-KQ19056 | Human | 7706 | Details Get a Quote |
| TRIM25 Knockout HeLa Cell Line | EDJ-KQ18315 | Human | 7706 | Details Get a Quote |
Displaying Records 1 To 4 Of 4 Records